SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

Adjuvant tamoxifen reduces the recurrence rate of estrogen receptor (ER)-positive breast cancer. Previous in vitro studies have suggested that tamoxifen can affect the cancerous inhibitor of protein phosphatase 2A (CIP2A)/protein phosphatase 2A (PP2A)/phosphorylation Akt (pAkt) signaling in ER-negat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yu-Hsiang Huang, Pei-Yi Chu, Ji-Lin Chen, Chun-Teng Huang, Chia-Han Lee, Ka-Yi Lau, Wan-Lun Wang, Yu-Ling Wang, Pei-Ju Lien, Ling-Ming Tseng, Chun-Yu Liu
Format: Artigo
Idioma:Inglês
Publicat: MDPI AG 2018-08-01
Col·lecció:Journal of Clinical Medicine
Matèries:
breast cancer
tamoxifen
SET
CIP2A
PP2A
Accés en línia:http://www.mdpi.com/2077-0383/7/9/245
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars